Attualità nellimpiego delle statine Prof. P. Pauletto Dip. di Medicina Clinica e Sperimentale Università degli Studi di Padova U.O. di Medicina Interna.
Psoriasis
Improve it slides
By Apurva D. Shah, FACC Northside Heart and Vascular Institute.
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and.
Residual risk: Is LDL target enough?. An interpretation of the continuous relationship between LDL-C and CVD Therefore, many men and most women with heart.
Common Questions in Lipids 2010 Mehul Bhatt, MD Athens Heart Center.
Efficacy of statins in primary and secondary prevention of CV events - well established Meta-analyses of RCTs : - demonstrated dramatic reductions in.
Cardiovascular New Drug Update C. Wayne Weart, Pharm D, FASHP, FAPhA, BCPS Professor of Clinical Pharmacy and Outcome Sciences South Carolina College of.
Role of Fenofibrate in Diabetic Dyslipidemia. Diabetic Dyslipidaemia Occurs in type 2 diabetes mellitus High levels of triglycerides Low levels of HDL-C.
LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.
